Bristol-myers Squibb

Bristol Myers Squibb launches heart medication Kopozgo in Indian market

Bristol Myers Squibb (BMS) on Wednesday announced the launch of Kopozgo (Mavacamten), an oral, selective cardiac myosin inhibitor, in India. Kopozgo is the first and only oral, selective cardiac myosin inhibitor approved in India for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM), BMS said in a statement. Mavacamten was approved by the Central Drugs Standard Control Organisation (CDSCO), with an import license issued on March 6, 2025. "Kopozgo is now available to patients in India. The approval of Kopozgo in India is based on positive efficacy and safety results from two Phase III clinical trials, EXPLORER-HCM and VALOR-HCM," the statement said. Sanjay Sharma, General Manager and Managing Director, BMS India, mentioned, "This breakthrough brings hope to individuals and families facing this condition, giving clinicians a novel therapy to address the unmet need in treatment. Bristol Myers Squibb is committed to advancing cardiovascular care fo

India to have largest R&D presence outside US by 2025: Bristol Myers CEO

Bristol Myers also operates a research and development centre in Bengaluru in partnership with the Biocon Group's Syngene International

Bristol Myers Squibb opens innovation hub worth $100 million in Hyderabad

"The state-of-the-art site will expand the company's global drug development and IT & digital capabilities and is expected to be home to over 1,500 employees," the company said in its release

Bristol-Myers, Sanofi to pay Hawaii $834 mn over Plavix warning label

Bristol-Myers and Sanofi, which produced Plavix in a partnership, in a joint statement vowed to appeal, saying the decision was "unsupported by the law and at odds with the evidence at trial"

Hubris therapy

Bristol-Myers suffers $21 bn self-inflicted wound